Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Salivary Gland Neoplasms 1Carcinoma, Adenoid Cystic 1

Interventions

Specimen Handling 71Magnetic Resonance Spectroscopy 57Biopsy 44pembrolizumab 38Carboplatin 32Nivolumab 29Cyclophosphamide 27Radiotherapy 26Radiation 25Paclitaxel 24Cisplatin 24olaparib 21Etoposide 19Doxorubicin 18durvalumab 17Taxes 17Radiotherapy, Intensity-Modulated 17Dexamethasone 17Bevacizumab 17X-Rays 16Vincristine 16Prednisone 16Immunoglobulin G 16Disulfides 16Cytarabine 15Platinum 14Leucovorin 14Docetaxel 14Pemetrexed 13Lenalidomide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Glutamate Carboxypeptidase II × 30 days × Clear all
NCT04895735 2026-06-04

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

Mayo Clinic

Phase 2 Active not recruiting
45 enrolled 12 charts
Head & Neck

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡